Reviva Pharmaceuticals Hldg Inc (RVPH) Stock Price, Quote & News

Company Profile

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity...

Industry: Biotechnology

Sector: Healthcare

Phone: 408-501-8881

Fax: 408-904-6270

Website: www.revivapharma.com

Address:

10080 N. Wolfe Road, Suite SW3-200, Cupertino, United States

Szeinaru Oct. 27 at 6:42 PM

$RVPH took a quick 150 profit on my new budget using $ASST hoping this falls a bit more so I can invest extra at .55

0 · Reply

MTN52C Oct. 27 at 6:20 PM

$RVPH this is not an if it's a when. Full on accumulation for me until then. If theres news of rs i'm porting out and sizing up my shares on the bottom, but for now it seems we are good until May 2026 which is more than enough to get this going to $1+ if nda meeting is positive in November-December

0 · Reply

Stockboi_ Oct. 27 at 6:07 PM

$RVPH support needs to hold here. Weekly is still strong

0 · Reply

MTN52C Oct. 27 at 5:57 PM

$RVPH RVPH: - Marketcap $65 million with approximately 96 million shares Second quarter reporting June 30 2025: - $113,246 in debt (low debt). This represents a significant decrease from the $458,154 in debt it reported at the end of 2024. - Total Assets: $11,630,000 - Total Liabilities: $12,093,993 - Cash on hand: $10,363,714 - Additional cash: $9 million public offering September 2025

0 · Reply

MTN52C Oct. 27 at 5:57 PM

$RVPH What is Brilaroxazine: - Brilaroxazine (RP5063) is an investigational drug being developed as a novel, third-generation antipsychotic for the treatment of schizophrenia. It is also being studied for other neuropsychiatric and neurological conditions, and preliminary clinical trial data have shown it can improve symptoms with a potentially favorable safety profile regarding weight gain, glucose, and lipid levels compared to other antipsychotics.

0 · Reply

MTN52C Oct. 27 at 5:56 PM

$RVPH - Brilaroxazine is unique due to its novel, multimodal mechanism that targets serotonin and dopamine systems to potentially improve efficacy and side effect profiles, with a key difference being its potent action on the 5-HT2B receptor. This specific receptor interaction is thought to help manage neuroinflammation, which could address negative and depressive symptoms, as well as cognitive issues, that current treatments struggle with. Furthermore, preliminary data suggests a favorable side effect profile, with minimal impact on movement disorders, weight gain, and other common adverse effects associated with older antipsychotics.

0 · Reply

MTN52C Oct. 27 at 5:55 PM

$RVPH - Serotonin and dopamine modulation:Unlike older drugs that focus primarily on D2 and 5-HT2A receptors, brilaroxazine is a partial agonist at D2, D3, D4, and 5-HT1A receptors, and also has potent antagonistic activity at 5-HT2B and 5-HT7 receptors. - Targeting neuroinflammation: Its potent activity on the 5-HT2B receptor is significant because this receptor is highly expressed in the brain and is implicated in neuroinflammation, which is a driver of schizophrenia symptoms. By modulating this receptor, brilaroxazine may offer benefits beyond symptom control.

0 · Reply

MTN52C Oct. 27 at 5:54 PM

$RVPH - Reduced motor side effects: Clinical trial data suggests brilaroxazine has minimal or no activity on targets known to cause motor side effects like akathisia and extrapyramidal symptoms. - Lower impact on weight gain: One study reported no significant weight gain in patients taking brilaroxazine. Other sources note a lack of drug-related serious adverse events and minimal weight gain in one-year studies. - Other benefits: Brilaroxazine also shows promise in addressing symptoms that are difficult to treat with current medications, such as negative symptoms, depressive symptoms, and cognitive impairment. - Brilaroxazine is generally a well-tolerated antipsychotic medication with a favorable safety profile. The most common side effects are mild and transient.

0 · Reply

MTN52C Oct. 27 at 5:53 PM

$RVPH Catalysts: - Brilaroxazine has completed phase 3 clinical trials for Schizophrenia. - Reviva is planning a meeting with the FDA in late 2025 to discuss the path to approval and could submit its New Drug Application (NDA) in the second quarter of 2026 brilaroxazine's use in schizophrenia. - Market launch after FDA approval

0 · Reply

MTN52C Oct. 27 at 5:53 PM

$RVPH Why RVPH is undervalued: Reviva Pharmaceuticals owns brilaroxazine and holds several patents on it, including the composition of matter patents for the compound itself and patents for its use in treating conditions like pulmonary fibrosis pulmonary hypertension and schizophrenia. The company discovered brilaroxazine in-house, and its intellectual property for the drug has been granted in countries including the United States, Europe, China, Japan, and Canada. Around 24 million people world wide is diagnosed with Schizophrenia. - United States: 3.7 million people - Europe: 4 million people - China: 5.3 million people - Japan: 1.9 million people

0 · Reply

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Sep 19, 2025, 7:01 AM EDT - 5 weeks ago

Top 3 Health Care Stocks That May Explode In September

ATYR BSX

Sep 18, 2025, 9:26 PM EDT - 5 weeks ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

Sep 18, 2025, 4:05 PM EDT - 5 weeks ago

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Aug 14, 2025, 4:25 PM EDT - 2 months ago

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jun 26, 2025, 8:40 AM EDT - 4 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Jun 5, 2025, 8:00 AM EDT - 5 months ago

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 2, 2025, 7:00 AM EDT - 5 months ago

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 15, 2025, 4:05 PM EDT - 5 months ago

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

Mar 30, 2025, 11:30 AM EDT - 7 months ago

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Feb 4, 2025, 8:00 AM EST - 9 months ago

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 8:00 AM EST - 9 months ago

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Jan 7, 2025, 8:00 AM EST - 10 months ago

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Dec 16, 2024, 5:18 PM EST - 11 months ago

Reviva Announces Proposed Public Offering

Dec 11, 2024, 3:37 PM EST - 11 months ago

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Nov 14, 2024, 5:25 PM EST - 1 year ago

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 6, 2024, 8:00 AM EST - 1 year ago

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the UBS Global Healthcare Conference

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Aug 21, 2024, 6:00 AM EDT - 1 year ago

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

May 29, 2024, 4:45 PM EDT - 1 year ago

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 28, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 21, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the BIO International Convention

May 15, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 14, 2024, 8:00 AM EDT - 1 year ago

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 13, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

May 9, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

Apr 15, 2024, 8:30 AM EDT - 1 year ago

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Apr 15, 2024, 8:05 AM EDT - 1 year ago

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present at the UBS Virtual CNS Day

Mar 7, 2024, 8:00 AM EST - 1 year ago

Reviva to Present at the 36th Annual ROTH Conference

Feb 20, 2024, 8:00 AM EST - 1 year ago

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Jan 25, 2024, 8:00 AM EST - 1 year ago

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Jan 10, 2024, 8:00 AM EST - 1 year ago

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Jan 4, 2024, 8:00 AM EST - 1 year ago

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Dec 11, 2023, 8:00 AM EST - 2 years ago

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Nov 30, 2023, 4:05 PM EST - 2 years ago

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 20, 2023, 4:05 PM EST - 2 years ago

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 8:00 AM EST - 2 years ago

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 14, 2023, 4:01 PM EST - 2 years ago

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 2, 2023, 3:11 AM EDT - 2 years ago

Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started

Oct 30, 2023, 7:41 AM EDT - 2 years ago

Reviva Pharma's schizophrenia drug succeeds in late-stage study

Oct 30, 2023, 7:30 AM EDT - 2 years ago

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Szeinaru Oct. 27 at 6:42 PM

$RVPH took a quick 150 profit on my new budget using $ASST hoping this falls a bit more so I can invest extra at .55

0 · Reply

MTN52C Oct. 27 at 6:20 PM

0 · Reply

Stockboi_ Oct. 27 at 6:07 PM

$RVPH support needs to hold here. Weekly is still strong

0 · Reply

MTN52C Oct. 27 at 5:57 PM

0 · Reply

MTN52C Oct. 27 at 5:57 PM

0 · Reply

MTN52C Oct. 27 at 5:56 PM

0 · Reply

MTN52C Oct. 27 at 5:55 PM

0 · Reply

MTN52C Oct. 27 at 5:54 PM

0 · Reply

MTN52C Oct. 27 at 5:53 PM

0 · Reply

MTN52C Oct. 27 at 5:53 PM

0 · Reply

MTN52C Oct. 27 at 5:52 PM

$RVPH - Reviva Pharmaceuticals Holdings, Inc. (RVPH) is planning to market Brilaroxazine in the United States, Europe, China, and Japan. - Brand name schizophrenia medications vary widely in price, with a 30-day supply potentially costing anywhere from around $190 to over $1.X,400 - The U.S. schizophrenia market was approximately $2.X.84 billion in 2024 and is projected to grow to $12.78 billion by 2032 - Brilaroxazine is being developed as a brand-name drug. Reviva Pharmaceuticals anticipates having exclusivity for Brilaroxazine until around 2045 - Reviva has stated its intent to develop brilaroxazine for other neuropsychiatric conditions beyond schizophrenia, including bipolar disorder, major depressive disorder (MDD), and attention-deficit/hyperactivity disorder (ADHD). - Inflammatory and cardiometabolic diseases: The company is also exploring the drug's potential in treating conditions such as psoriasis, pulmonary arterial hypertension (PAH), and idiopathic pulmonary fibrosis (IPF).

0 · Reply

MTN52C Oct. 27 at 5:52 PM

$RVPH - Orphan Drug Designations: Brilaroxazine has received Orphan Drug Designation from the U.S. FDA for both PAH and IPF, which may fast-track its development and provide marketing exclusivity for those conditions if approved. - Granted patents: Reviva has been granted U.S. and European patents covering the use of brilaroxazine for treating pulmonary hypertension and idiopathic pulmonary fibrosis, providing protection for those uses. - This broad development strategy indicates that Reviva is setting itself up to earn revenue from brilaroxazine in multiple treatment areas, not just schizophrenia

0 · Reply

MTN52C Oct. 27 at 5:49 PM

$RVPH Lets say approximately 14,900,000 people within these Countries (US, China, Europe and Japan) RVPH is targeting for Brilaroxazine. If 10% of these people decide to use Brilaroxazine that's 1,490,000 people x $190-500 = $238-745 million monthly revenue. That's 3.3-9 billion revenue annualy. These numbers are low ball park numbers. If Brilaroxazine is favored due to their safety profile and efficiency, they would perhaps dominate the market as a prefered choice for schizophrenia. In addition to the other conditions RVPH is planning to cater to beyond schizophrenia. RVPH is extremely undervalued and can 100x+ into a marketcap suited by their accumulated revenue once Brilaroxazine start to scale.

0 · Reply

MTN52C Oct. 27 at 5:47 PM

$RVPH i'm in 81,500 shares. planning to buy another 37,000 tomorrow and monthly average down $3000/monthly. Until fda meeting

0 · Reply

ERPBlast Oct. 27 at 5:12 PM

$RVPH nothing?

0 · Reply

Stockboi_ Oct. 27 at 4:24 PM

$RVPH added

0 · Reply

GibsonFlyingV Oct. 27 at 3:46 PM

$RVPH little by little is the game we play. Bought more this morning on the dip just below 0.60

0 · Reply

KingPurcy Oct. 27 at 3:38 PM

$AREB $INHD $RVPH $YYAI each one of these should be $5-$8 at least by eoy

1 · Reply

MTN52C Oct. 27 at 3:37 PM

$RVPH fk it i'm buying and accumulating RVPH is a forsure riser

1 · Reply

Whiskeyunderthebed Oct. 27 at 3:04 PM

$RVPH In order for a short squeeze to happen- we would need over 60M-70M shares to trade.

0 · Reply

ERPBlast Oct. 27 at 2:51 PM

$RVPH short squize?

0 · Reply

Bigtradesbigprofit Oct. 27 at 2:38 PM

$RVPH bought some $1 calls this morning

0 · Reply

Market Cap	46.82M
Revenue (ttm)	0.00
Net Income (ttm)	-29.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	10,815,140
Avg Vol	10,939,872
Day's Range	N/A - N/A
Shares Out	69.34M
Stochastic %K	91%
Beta	-0.08
Analysts	Strong Sell
Price Target	$6.25